GlassScriptPhysician profile
Aishah Covington Simms
NPI 1316202278
$6,348.41
in general payments reported to CMS, 2019-2025
43 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $827 · 2021: $894 · 2022: $591 · 2023: $917 · 2024: $904 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $917.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $833.36 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $699.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $458.74 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $456.40 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $437.16 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $423.27 | 2019-2025 | |
| Astellas Pharma US INC | $191.97 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.66 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.27 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $110.95 | 2019-2021 | |
| Abbott Laboratories | $106.04 | 2023-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Dynavax Technologies Corporation | $97.24 | 2023-2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $95.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $92.91 | 2019-2025 | Gardasil 9, Capvaxive |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aishah Covington Simms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.